Partial agonism and antagonism of the ionotropic glutamate receptor iGLuR5 - Structures of the ligand-binding core in complex with domoic acid and 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid

被引:50
作者
Hald, Helle
Naur, Peter
Pickering, Darryl S.
Sprogoe, Desiree
Madsen, Ulf
Timmermann, Daniel B.
Ahring, Philip K.
Liljefors, Tommy
Schousboe, Arne
Egebjerg, Jan
Gajhede, Michael
Kastrup, Jette Sandholm
机构
[1] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] Univ Copenhagen, Fac Pharmaceut Sci, Dept Pharmacol & Pharmacotherapy, DK-2100 Copenhagen, Denmark
[3] H Lundbeck & Co AS, DK-2500 Copenhagen, Denmark
[4] NeuroSearch AS, DK-2750 Ballerup, Denmark
关键词
D O I
10.1074/jbc.M700137200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 50 structures have been reported on the ligandbinding core of the ionotropic glutamate receptor iGluR2 that belongs to the 2-amino- 3-(3- hydroxy-5-methyl-4-isoxazolyl) propionic acid-type of receptors. In contrast, the ligand-binding core of the kainic acid-type receptor iGluR5 has only been crystallized with three different ligands. Hence, additional structures of iGluR5 are needed to broaden the understanding of the ligand-binding properties of iGluR5, and the conformational changes leading to channel opening and closing. Here, we present two structures of the ligandbinding core of iGluR5; one as a complex with the partial agonist (2S, 3S, 4S)-3-carboxymethyl- 4-[(1Z, 3E, 5R)-5-carboxy-1methyl- hexa-1,3-dienyl]- pyrrolidine- 2-carboxylic acid ( domoic acid) and one as a complex with the antagonist ( S)- 2-amino- 3[ 5-tert-butyl-3-( phosphonomethoxy)- 4- isoxazolyl] propionic acid (( S)- ATPO). In agreement with the partial agonist activity of domoic acid, the ligand-binding core of the iGluR5 complex is stabilized by domoic acid in a conformation that is 11 more open than the conformation observed in the full agonist ( S)glutamic acid complex. This is primarily caused by the 5-carboxy1- methyl-hexa-1,3- dienyl moiety of domoic acid and residues Val(685)-Thr(690) of iGluR5. An even larger domain opening of 28 is introduced upon binding of the antagonist ( S)- ATPO. It appears that the span of domain opening is much larger in the ligand-binding core of iGluR5 ( 30) compared with what has been observed in iGluR2 ( 19). Similarly, much larger variation in the distances between transmembrane linker residues in the two protomers comprising the dimer is observed in iGluR5 as compared with iGluR2.
引用
收藏
页码:25726 / 25736
页数:11
相关论文
共 59 条
[1]   Mechanisms for activation and antagonism of an AMPA-Sensitive glutamate receptor: Crystal structures of the GluR2 ligand binding core [J].
Armstrong, N ;
Gouaux, E .
NEURON, 2000, 28 (01) :165-181
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]  
Berman FW, 1997, J NEUROCHEM, V69, P693
[4]   CLONING OF A NOVEL GLUTAMATE RECEPTOR SUBUNIT, GLUR5 - EXPRESSION IN THE NERVOUS-SYSTEM DURING DEVELOPMENT [J].
BETTLER, B ;
BOULTER, J ;
HERMANSBORGMEYER, I ;
OSHEAGREENFIELD, A ;
DENERIS, ES ;
MOLL, C ;
BORGMEYER, U ;
HOLLMANN, M ;
HEINEMANN, S .
NEURON, 1990, 5 (05) :583-595
[5]   CLONING OF A PUTATIVE GLUTAMATE RECEPTOR - A LOW AFFINITY KAINATE-BINDING SUBUNIT [J].
BETTLER, B ;
EGEBJERG, J ;
SHARMA, G ;
PECHT, G ;
HERMANSBORGMEYER, I ;
MOLL, C ;
STEVENS, CF ;
HEINEMANN, S .
NEURON, 1992, 8 (02) :257-265
[6]   Ligands for glutamate receptors:: Design and therapeutic prospects [J].
Bräuner-Osborne, H ;
Egebjerg, J ;
Nielsen, EO ;
Madsen, U ;
Krogsgaard-Larsen, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2609-2645
[7]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[8]  
*CHEM COMP GROUP I, 2006, MOE SOFTW
[9]  
DeLano W. L., 2002, PYMOL
[10]  
Dingledine R, 1999, PHARMACOL REV, V51, P7